Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.
Condition or disease
Sarcoma, KaposiHIV Infections
Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in 33% increments. Study drug is administered as a twice-weekly intravenous injection for 4 weeks. In the absence of unacceptable toxicity, responding patients may continue on SU5416 in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable toxicity or tumor progression.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
You may be eligible for this study if you:
Are at least 18 years old.
Have KS with at least 5 skin lesions.
Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy.
Agree to use effective methods of birth control during the study.
You will not be eligible for this study if you:
Have had surgery within 4 weeks of study entry.
Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry.
Have pulmonary KS (KS in your lungs).
Have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers.
Are allergic to Cremophor.
Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy).
Gill P, Arasteh K, Jacobs M, Friedman-Kiel A, Miles S, Gracey S, Hannah A, Langecker P. A multicenter, dose-escalating study in patients with AIDS-related Kaposi's Sarcoma 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sept 26-29